Evaluation_NN of_IN GenoType_NP and_CC LiPA_NP MYCOBACTERIA_NP Assays_NP for_IN Identification_NN of_IN Finnish_JJ Mycobacterial_NP Isolates_NP Two_NP DNA_NP strip_NN assays_NNS ,_, INNO-LiPA_NP MYCOBACTERIA_NP and_CC GenoType_NP Mykobakterien_NP ,_, were_VBD evaluated_VBN for_IN identification_NN of_IN 81_CD Finnish_JJ mycobacterial_JJ isolates_NNS ._SENT The_DT LiPA_NP assay_NN correctly_RB identified_VBD 89.4_CD %_NN of_IN the_DT 66_CD isolates_NNS studied_VBN ,_, and_CC the_DT GenoType_NP assay_NN identified_VBD 95.1_CD %_NN of_IN 81_CD isolates_NNS ._SENT The_DT GenoType_NP assay_NN had_VBD a_DT wider_JJR selection_NN of_IN species_NNS and_CC less_JJR stringent_JJ temperature_NN requirements_NNS ._SENT Of_IN the_DT more_JJR than_IN 100_CD mycobacterial_JJ species_NNS identified_VBN to_TO date_NN ,_, at_IN least_JJS 21_CD are_VBP pathogenic_JJ to_TO humans_NNS and_CC frequently_RB isolated_VBN from_IN clinical_JJ samples_NNS ._SENT Immunocompromised_JJ patients_NNS are_VBP especially_RB vulnerable_JJ to_TO opportunistic_JJ infections_NNS caused_VBN by_IN mycobacteria_NNS other_JJ than_IN Mycobacterium_NN tuberculosis_NN (_( MOTT_NP )_) ._SENT MOTT_NP infections_NNS usually_RB occur_VBP in_IN developed_VBN countries_NNS ,_, where_WRB the_DT incidence_NN of_IN tuberculosis_NN is_VBZ low_JJ ,_, whereas_IN in_IN developing_VBG countries_NNS M._NP tuberculosis_NN remains_VBZ the_DT most_RBS common_JJ cause_NN of_IN mycobacterial_JJ disease_NN ._SENT The_DT increasing_VBG incidence_NN of_IN MOTT_NP infections_NNS has_VBZ made_VBN it_PP important_JJ to_TO rapidly_RB identify_VB mycobacteria_NNS at_IN the_DT species_NN level_NN ,_, as_IN treatment_NN varies_VBZ according_VBG to_TO the_DT species_NNS responsible_JJ for_IN the_DT infection_NN ._SENT Molecular_JJ biological_JJ methods_NNS such_JJ as_IN DNA_NP sequencing_NP ,_, PCR-restriction_NN fragment_NN length_NN polymorphism_NN (_( RFLP_NP )_) assays_NNS ,_, and_CC commercial_JJ tests_NNS such_JJ as_IN the_DT AccuProbe_NP (_( Gen-Probe_NP Inc._NP ,_, San_NP Diego_NP ,_, Calif._NP )_) have_VBP replaced_VBN conventional_JJ biochemical_JJ tests_NNS for_IN the_DT identification_NN of_IN mycobacteria_NNS ._SENT The_DT new_JJ methods_NNS have_VBP greatly_RB improved_VBN both_CC the_DT speed_NN and_CC accuracy_NN of_IN mycobacterial_JJ diagnostics_NNS ._SENT However_RB ,_, the_DT methods_NNS have_VBP their_PP$ limitations_NNS :_: DNA_NP sequencing_NP is_VBZ rather_RB time-consuming_JJ and_CC requires_VBZ expensive_JJ equipment_NN ,_, while_IN the_DT differentiation_NN of_IN mycobacterial_JJ species_NNS by_IN PCR-RFLP_NP requires_VBZ the_DT use_NN of_IN several_JJ restriction_NN enzymes_NNS ._SENT The_DT drawback_NN of_IN the_DT AccuProbe_NP test_NN is_VBZ the_DT limited_JJ number_NN of_IN species_NNS that_WDT can_MD be_VB identified_VBN ._SENT Recently_RB ,_, DNA_NP strip_NN technology_NN ,_, based_VBN on_IN the_DT reverse_JJ hybridization_NN of_IN PCR_NP products_NNS to_TO their_PP$ complementary_JJ probes_NNS ,_, has_VBZ been_VBN applied_VBN to_TO simultaneous_JJ detection_NN and_CC identification_NN of_IN mycobacteria_NNS ._SENT Currently_RB ,_, two_CD DNA_NN strip_NN assays_NNS ,_, INNO-LiPA_NP MYCOBACTERIA_NP (_( Innogenetics_NP N.V._NP ,_, Ghent_NP ,_, Belgium_NP )_) (_( LiPA_NP )_) and_CC GenoType_NP Mykobakterien_NP (_( Hain_NP Lifescience_NP GmbH_NP ,_, Nehren_NP ,_, Germany_NP )_) (_( GenoType_NP )_) ,_, are_VBP commercially_RB available_JJ ._SENT Both_DT assays_NNS provide_VBP probes_NNS for_IN the_DT M._NP tuberculosis_NN complex_NN ,_, Mycobacterium_NN avium_NN ,_, Mycobacterium_NP intracellulare_NP ,_, Mycobacterium_NP kansasii_NP ,_, Mycobacterium_NN chelonae_NNS ,_, Mycobacterium_NN gordonae_NNS ,_, Mycobacterium_NP xenopi_NP ,_, and_CC Mycobacterium_NN scrofulaceum_NN ._SENT In_IN addition_NN ,_, the_DT LiPA_NP strip_NN can_MD identify_VB members_NNS of_IN the_DT M._NP avium_NN complex_NN and_CC differentiate_VB between_IN the_DT three_CD M._NP chelonae_NNS and_CC three_CD M._NP kansasii_NN subgroups_NNS ._SENT The_DT GenoType_NP strip_NN has_VBZ additional_JJ probes_NNS for_IN Mycobacterium_NN celatum_NN ,_, Mycobacterium_NN malmoense_NN ,_, Mycobacterium_NP peregrinum_NP ,_, Mycobacterium_NP phlei_NP ,_, and_CC two_CD subgroups_NNS of_IN Mycobacterium_NN fortuitum_NN ._SENT The_DT performance_NN of_IN the_DT LiPA_NP test_NN has_VBZ been_VBN assessed_VBN using_VBG BACTEC_NP 12B_NP bottles_NNS on_IN a_DT panel_NN of_IN clinical_JJ isolates_NNS from_IN the_DT United_NP States_NPS and_CC on_IN clinical_JJ isolates_NNS collected_VBN from_IN Brazil_NP and_CC Italy_NP ._SENT To_TO our_PP$ knowledge_NN ,_, the_DT GenoType_NP test_NN has_VBZ not_RB been_VBN evaluated_VBN previously_RB ._SENT Since_IN intraspecies_NN variation_NN within_IN mycobacteria_NNS isolated_VBN from_IN different_JJ geographical_JJ regions_NNS has_VBZ been_VBN reported_VBN ,_, we_PP wanted_VBD to_TO assess_VB the_DT capability_NN of_IN the_DT two_CD assays_NNS to_TO correctly_RB detect_VB and_CC identify_VB mycobacterial_JJ isolates_NNS obtained_VBN from_IN patients_NNS living_VBG in_IN Finland_NP ._SENT Further_RBR ,_, the_DT two_CD tests_NNS were_VBD compared_VBN for_IN cost-effectiveness_NN ,_, ease_NN of_IN use_NN ,_, and_CC interpretation_NN of_IN results_NNS ._SENT Eighty-one_NP clinical_JJ mycobacterial_JJ isolates_NNS were_VBD selected_VBN from_IN the_DT strain_NN collection_NN of_IN the_DT Mycobacterial_NP Reference_NP Laboratory_NP ,_, National_NP Public_NP Health_NP Institute_NP ,_, Turku_NP ,_, Finland_NP ._SENT The_DT strains_NNS were_VBD isolated_VBN in_IN 1990-2001_CD from_IN patients_NNS living_VBG in_IN Finland_NP ._SENT The_DT isolates_NNS were_VBD chosen_VBN to_TO represent_VB the_DT mycobacterial_JJ species_NN identified_VBN by_IN the_DT two_CD tests_NNS ._SENT The_DT isolates_NNS had_VBD been_VBN identified_VBN to_TO species_NN level_NN either_CC by_IN the_DT AccuProbe_NP test_NN (_( Gen-Probe_NP Inc._NP )_) or_CC by_IN 16S_JJ ribosomal_JJ DNA_NN (_( rDNA_NN )_) sequencing_NP and_CC phenotypic_JJ characteristics_NNS ._SENT Members_NNS of_IN the_DT M._NP tuberculosis_NN complex_NN had_VBD been_VBN further_RBR differentiated_VBN using_VBG the_DT nitrate_NN test_NN and_CC allele-specific_JJ amplification_NN ._SENT The_DT bacteria_NNS were_VBD cultivated_VBN on_IN Lowenstein-Jensen_NP medium_NN and_CC incubated_VBN at_IN 37C_JJ ._SENT For_IN the_DT GenoType_NP and_CC LiPA_NP assays_NNS ,_, DNA_NP was_VBD prepared_VBN according_VBG to_TO the_DT LiPA_NP manufacturer_NN 's_POS instructions_NNS by_IN boiling_VBG at_IN 100C_NP for_IN 10_CD min_NN and_CC centrifuging_VBG at_IN 13,000_CD rpm_NN (_( centrifuge_NN 5415D_NN ;_: Eppendorf_NP AG_NP ,_, Hamburg_NP ,_, Germany_NP )_) for_IN 5_CD min_NN ._SENT TABLE_NN 1_CD |_SYM Identification_NN of_IN mycobacterial_JJ isolates_NNS by_IN LiPA_NP and_CC GenoType_NP assays_VBZ The_DT assays_NNS were_VBD carried_VBN out_IN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ,_, using_VBG the_DT reagents_NNS provided_VBN with_IN the_DT LiPA_NP and_CC GenoType_NP kits_NNS ._SENT Both_DT protocols_NNS consisted_VBN of_IN PCR_NP amplification_NN ,_, hybridization_NN of_IN the_DT PCR_NP products_NNS to_TO the_DT strips_NNS ,_, and_CC detection_NN and_CC interpretation_NN of_IN the_DT results_NNS ._SENT Table_NN summarizes_VBZ the_DT results_NNS of_IN both_DT assays_NNS ._SENT The_DT results_NNS of_IN PCR_NP amplification_NN were_VBD always_RB confirmed_VBN by_IN gel_NN electrophoresis_NN ._SENT LiPA_NP PCR_NP ,_, targeting_VBG the_DT 16S-23S_JJ rRNA_NN spacer_NN region_NN ,_, yielded_VBD 400-_CD to_TO 550-bp_JJ amplicons_NNS for_IN 78_CD of_IN the_DT 81_CD isolates_NNS studied_VBD ._SENT The_DT three_CD isolates_NNS ,_, which_WDT remained_VBD negative_JJ in_IN LiPA_NP PCR_NP ,_, despite_IN repeated_VBN attempts_NNS ,_, had_VBD been_VBN identified_VBN as_IN M._NP chelonae_NNS by_IN 16S_NP rDNA_NP sequencing_NP ._SENT The_DT same_JJ DNA_NN preparations_NNS of_IN the_DT three_CD isolates_NNS were_VBD successfully_RB amplified_VBN by_IN GenoType_NP PCR_NP ,_, which_WDT targets_VBZ the_DT 23S_JJ rDNA_NN ,_, and_CC identified_VBN by_IN the_DT GenoType_NP assay_NN as_IN M._NP chelonae_NNS ._SENT With_IN GenoType_NP PCR_NP ,_, the_DT approximately_RB 200-bp_JJ amplicons_NNS were_VBD detected_VBN for_IN 80_CD of_IN the_DT 81_CD isolates_NNS studied_VBD ._SENT The_DT one_CD isolate_NN that_WDT constantly_RB remained_VBD negative_JJ in_IN GenoType_NP PCR_NP had_VBD been_VBN identified_VBN as_IN M._NP intracellulare_NN by_IN the_DT reference_NN methods_NNS ._SENT The_DT same_JJ DNA_NN was_VBD successfully_RB amplified_VBN in_IN LiPA_NP PCR_NP and_CC correctly_RB identified_VBN as_IN M._NP intracellulare_NN ._SENT In_IN both_DT assays_NNS ,_, all_DT isolates_NNS that_WDT were_VBD PCR_NP positive_NN hybridized_VBD to_TO the_DT Mycobacterium_NP genus_NN probe_NN ._SENT As_IN the_DT LiPA_NP strip_NN has_VBZ no_DT species-specific_JJ probes_NNS for_IN M._NP celatum_NN ,_, M._NP fortuitum_NN ,_, and_CC M._NP peregrinum_NP ,_, the_DT assay_NN was_VBD evaluated_VBN using_VBG the_DT 66_CD strains_NNS with_IN species_NNS in_IN the_DT identification_NN range_NN of_IN LiPA_NP ._SENT Moreover_RB ,_, the_DT LiPA_NP assay_NN has_VBZ no_DT species-specific_JJ probe_NN for_IN M._NP malmoense_NN ,_, but_CC this_DT species_NN is_VBZ positive_JJ with_IN the_DT M._NP avium-M_NN ._SENT intracellulare-M_NN ._SENT scrofulaceum_NN complex_NN (_( MAIS_NP )_) probe_NN ._SENT If_IN identification_NN at_IN the_DT MAIS_NP complex_JJ level_NN is_VBZ considered_VBN correct_JJ ,_, the_DT LiPA_NP assay_NN correctly_RB identified_VBD 59_CD of_IN the_DT 66_CD (_( 89.4_CD %_NN )_) strains_NNS ._SENT However_RB ,_, when_WRB the_DT nine_CD M._NP malmoense_NN strains_NNS were_VBD excluded_VBN from_IN the_DT study_NN ,_, the_DT LiPA_NP assay_NN correctly_RB identified_VBD 50_CD of_IN the_DT 57_CD (_( 87.7_CD %_NN )_) isolates_VBZ at_IN the_DT species_NN level_NN ._SENT The_DT seven_CD strains_NNS that_IN the_DT LiPA_NP test_NN failed_VBD to_TO identify_VB correctly_RB included_VBD the_DT three_CD M._NP chelonae_NNS strains_NNS that_WDT remained_VBD PCR_NP negative_JJ ,_, two_CD M._NP intracellulare_NN strains_NNS ,_, and_CC two_CD M._NP scrofulaceum_NN strains_NNS ._SENT M._NP intracellulare_NN is_VBZ detected_VBN by_IN positive_JJ hybridization_NN to_TO two_CD probes_NNS ,_, MAIS_NP and_CC MIN_NP ._SENT Of_IN the_DT two_CD M._NP intracellulare_NN strains_NNS ,_, one_PP reacted_VBD with_IN the_DT MAIS_NP probe_NN alone_RB and_CC the_DT other_JJ with_IN the_DT MIN_NP probe_NN alone_RB ._SENT The_DT M._NP scrofulaceum_NN strains_NNS are_VBP detected_VBN by_IN positive_JJ hybridization_NN to_TO two_CD probes_NNS ,_, MAIS_NP and_CC MSC_NP ._SENT Of_IN the_DT two_CD M._NP scrofulaceum_NN strains_NNS ,_, one_PP reacted_VBD with_IN the_DT MAIS_NP probe_NN alone_RB and_CC the_DT other_JJ with_IN the_DT Mycobacterium_NN genus_NN (_( MYC_NP )_) probe_NN only_RB ._SENT Interestingly_RB ,_, the_DT two_CD M._NP intracellulare_NN strains_VBZ that_IN the_DT LiPA_NP assay_NN failed_VBD to_TO identify_VB correctly_RB could_MD not_RB be_VB identified_VBN by_IN the_DT GenoType_NP assay_NN either_RB ._SENT The_DT GenoType_NP assay_NN correctly_RB identified_VBD 77_CD of_IN the_DT 81_CD (_( 95.1_CD %_NN )_) strains_NNS when_WRB compared_VBN to_TO the_DT reference_NN methods_NNS ._SENT One_CD M._NP intracellulare_NN strain_NN remained_VBD PCR_NP negative_JJ ._SENT In_IN addition_NN ,_, two_CD M._NP intracellulare_NN isolates_NNS and_CC one_CD M._NP avium_NN isolate_NN were_VBD not_RB correctly_RB identified_VBN ._SENT In_IN GenoType_NP strips_NNS ,_, M._NP intracellulare_NP is_VBZ detected_VBN by_IN positive_JJ hybridization_NN to_TO probes_NNS 9_CD and_CC 11_CD ._SENT Of_IN the_DT two_CD M._NP intracellulare_NN strains_NNS ,_, one_PP reacted_VBD with_IN probe_NN 9_CD alone_RB and_CC the_DT other_JJ with_IN probe_NN 11_CD alone_RB ._SENT M._NP avium_NN is_VBZ identified_VBN by_IN positive_JJ hybridization_NN to_TO probes_NNS 3_CD and_CC 11_CD ._SENT The_DT incorrectly_RB identified_VBN M._NP avium_NN strain_NN reacted_VBD only_RB with_IN probe_NN 11_CD ._SENT Representative_JJ examples_NNS of_IN the_DT strips_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT FIG._NN 1_CD ._SENT |_SYM Examples_NNS of_IN the_DT results_NNS of_IN the_DT LiPA_NP (_( A_NP )_) and_CC GenoType_NP (_( B_NP )_) line_NN probe_NN assays_NNS ._SENT Examples_NNS of_IN the_DT results_NNS of_IN the_DT LiPA_NP (_( A_NP )_) and_CC GenoType_NP (_( B_NP )_) line_NN probe_NN assays_NNS ._SENT The_DT results_NNS for_IN the_DT same_JJ isolate_NN are_VBP shown_VBN for_IN each_DT of_IN the_DT species_NN ._SENT The_DT position_NN of_IN the_DT probes_NNS is_VBZ shown_VBN on_IN the_DT right_NN ._SENT Lanes_NNS :_: 1_LS ,_, M._NP scrofulaceum_NP ;_: 2_LS ,_, M._NP malmoense_NP ;_: 3_LS ,_, M._NP avium_NN ;_: 4_LS ,_, M._NP chelonae_NNS ;_: 5_LS ,_, M._NP tuberculosis_NN ;_: 6_CD ,_, M._NP kansasii_NP ;_: 7_CD ,_, M._NP intracellulare_NP ;_: 8_CD ,_, M._NP xenopi_NP ;_: 9_CD ,_, M._NP gordonae_NNS ._SENT The_DT LiPA_NP assay_NN further_RBR differentiates_VBZ M._NP kansasii_NP strains_NNS to_TO subgroups_NNS I_PP ,_, II_NP ,_, and_CC III-V_NP Mycobacterium_NP gastri_NP ._SENT Of_IN the_DT six_CD M._NP kansasii_NNS strains_NNS studied_VBD ,_, three_CD belonged_VBD to_TO subgroup_NN II_NP ,_, two_CD to_TO subgroup_NN III-V_NP ,_, and_CC one_CD to_TO subgroup_NN I._NN The_DT LiPA_NP test_NN also_RB differentiates_VBZ M._NP chelonae_NNS strains_NNS to_TO subgroups_NNS with_IN three_CD MCH_NP probes_NNS ,_, namely_RB MCH-1_JJ (_( groups_NNS I_PP ,_, II_NP ,_, III_NP ,_, and_CC IV_NP )_) ,_, MCH-2_NP (_( group_NN III_NP )_) ,_, and_CC MCH-3_NP (_( group_NN I_CD )_) ._SENT All_DT five_CD M._NP chelonae_NNS strains_NNS reacted_VBD with_IN the_DT MCH-1_JJ probe_NN ,_, but_CC not_RB with_IN MCH-2_NP or_CC MCH-3_NP ._SENT Thus_RB ,_, the_DT strains_NNS represent_VBP group_NN II_NP and/or_CC group_NN IV_NP ._SENT In_IN addition_NN to_TO the_DT species-specific_JJ probes_NNS ,_, both_CC assays_NNS have_VBP a_DT conjugate_JJ control_NN line_NN on_IN the_DT strip_NN to_TO ensure_VB that_IN reactive_JJ conjugate_JJ and_CC substrate_NN have_VBP been_VBN added_VBN ._SENT The_DT LiPA_NP assay_NN also_RB has_VBZ hybridization_NN temperature_NN controls_NNS ._SENT During_IN this_DT study_NN ,_, LiPA_NP strips_NNS constantly_RB indicated_VBD that_IN the_DT hybridization_NN temperature_NN was_VBD too_RB low_JJ by_IN giving_VBG faint_JJ bands_NNS at_IN probes_NNS MCH-1_NP and_CC MKA-2_NP ,_, despite_IN prewarmed_JJ reagents_NNS and_CC correct_JJ temperature_NN in_IN the_DT water_NN bath_NN ._SENT However_RB ,_, this_DT did_VBD not_RB lead_VB to_TO misidentification_NN of_IN isolates_NNS ._SENT Two_CD novel_NN line_NN probe_NN assays_NNS ,_, LiPA_NP and_CC GenoType_NP ,_, were_VBD evaluated_VBN for_IN identification_NN of_IN 81_CD mycobacterial_JJ isolates_NNS obtained_VBN from_IN Finnish_JJ patients_NNS ._SENT The_DT assays_NNS were_VBD compared_VBN to_TO reference_NN methods_NNS AccuProbe_NP and_CC 16S_NP rDNA_NP sequencing_NP ._SENT The_DT LiPA_NP assay_NN correctly_RB identified_VBD 89.4_CD %_NN (_( 59_CD of_IN 66_CD )_) of_IN the_DT clinical_JJ isolates_NNS within_IN the_DT identification_NN range_NN of_IN the_DT test_NN ,_, while_IN the_DT GenoType_NP correctly_RB identified_VBD 95.1_CD %_NN (_( 77_CD of_IN 81_CD )_) ._SENT Both_DT assays_NNS were_VBD rapid_JJ ,_, reliable_JJ ,_, and_CC easy_JJ to_TO perform_VB ._SENT The_DT different_JJ targets_NNS may_MD explain_VB the_DT differences_NNS seen_VBN in_IN the_DT performance_NN of_IN the_DT three_CD tests_NNS ._SENT The_DT targets_NNS of_IN the_DT AccuProbe_NP system_NN (_( 16S_JJ rRNA_NN )_) and_CC the_DT GenoType_NP assay_NN (_( 23S_JJ rDNA_NN )_) contain_VBP conserved_VBN and_CC variable_JJ regions_NNS ,_, but_CC the_DT LiPA_NP target_NN (_( 16S-23S_JJ spacer_NN )_) is_VBZ known_VBN to_TO be_VB more_RBR polymorphic_JJ (_( -_: ,_, )_) ._SENT Balance_NN between_IN suitable_JJ variation_NN for_IN species_NN differentiation_NN and_CC stability_NN for_IN successful_JJ long-term_JJ performance_NN is_VBZ crucial_JJ ._SENT In_IN previous_JJ reports_NNS ,_, the_DT LiPA_NP assay_NN has_VBZ correctly_RB identified_VBN more_JJR than_IN 99.4_CD %_NN of_IN isolates_NNS studied_VBN ._SENT The_DT performance_NN of_IN the_DT GenoType_NP assay_NN has_VBZ not_RB been_VBN evaluated_VBN before_RB ._SENT In_IN our_PP$ study_NN ,_, the_DT LiPA_NP assay_NN correctly_RB identified_VBD 89.4_CD %_NN of_IN the_DT strains_NNS and_CC GenoType_NP correctly_RB identified_VBD 95.1_CD %_NN of_IN the_DT strains_NNS ._SENT This_DT is_VBZ the_DT first_JJ study_NN with_IN LiPA_NP PCR_NP failing_VBG to_TO amplify_VB some_DT (_( 3_CD of_IN 81_CD )_) of_IN the_DT strains_NNS and_CC a_DT similar_JJ defect_NN was_VBD found_VBN in_IN the_DT GenoType_NP assay_NN (_( 1_CD of_IN 81_CD strains_NNS )_) ._SENT The_DT difference_NN between_IN the_DT results_NNS of_IN our_PP$ study_NN and_CC previously_RB reported_VBD LiPA_NP test_NN performance_NN probably_RB reflects_VBZ the_DT genetic_JJ variation_NN observed_VBN in_IN mycobacterial_JJ subspecies_NN isolated_VBN from_IN different_JJ geographical_JJ areas_NNS ._SENT Although_IN all_DT strains_NNS were_VBD not_RB identified_VBN at_IN the_DT complex_NN or_CC species_NN level_NN ,_, as_IN planned_VBN ,_, no_DT interspecies_NNS cross-reactivity_NN was_VBD found_VBN ._SENT Although_IN we_PP did_VBD not_RB evaluate_VB the_DT sensitivity_NN of_IN line_NN probe_NN assays_NNS ,_, the_DT PCR_NP amplification_NN step_NN clearly_RB makes_VBZ line_NN probe_NN assays_VBZ more_RBR sensitive_JJ than_IN the_DT AccuProbe_NP test_NN ._SENT Further_RBR ,_, as_IN Tortoli_NP et_FW al._FW have_VBP pointed_VBN out_RP ,_, the_DT LiPA_NP assay_NN as_RB well_RB as_IN the_DT GenoType_NP assay_NN have_VBP the_DT advantage_NN of_IN targeting_VBG stable_JJ DNA_NN ,_, whereas_IN the_DT AccuProbe_NP test_NN targets_VBZ unstable_JJ rRNA_NN and_CC therefore_RB requires_VBZ a_DT substantial_JJ amount_NN not_RB only_RB of_IN bacteria_NNS but_CC also_RB of_IN viable_JJ organisms_NNS ._SENT LiPA_NP strips_NNS can_MD further_RBR differentiate_VB M._NP kansasii_NP and_CC M._NP chelonae_NNS strains_NNS into_IN subtypes_NNS ._SENT As_IN the_DT clinical_JJ differences_NNS of_IN the_DT five_CD M._NP kansasii_NN subtypes_NNS are_VBP known_VBN ,_, this_DT information_NN is_VBZ valuable_JJ for_IN appropriate_JJ patient_JJ management_NN ._SENT The_DT clinical_JJ importance_NN of_IN M._NP chelonae_NNS subtypes_NNS is_VBZ not_RB known_VBN and_CC ,_, therefore_RB ,_, the_DT additional_JJ information_NN provided_VBN by_IN the_DT LiPA_NP is_VBZ merely_RB of_IN epidemiological_JJ value_NN ._SENT The_DT fact_NN that_IN LiPA_NP PCR_NP only_RB amplified_VBD 62.5_CD %_NN (_( 5_CD of_IN 8_CD )_) of_IN M._NP chelonae_NNS strains_NNS included_VBD in_IN this_DT study_NN shows_VBZ the_DT intraspecies_NNS heterogeneity_NN of_IN the_DT 16S-23S_JJ rRNA_NN spacer_NN region_NN for_IN this_DT species_NN ._SENT All_DT M._NP chelonae_NN isolates_NNS were_VBD amplified_VBN and_CC correctly_RB identified_VBN by_IN the_DT GenoType_NP assay_NN ,_, possibly_RB reflecting_VBG the_DT suitable_JJ genetic_JJ stability_NN of_IN the_DT 23S_JJ rDNA_NN ._SENT Both_CC strip_NN assays_NNS performed_VBD very_RB similarly_RB in_IN the_DT laboratory_NN ._SENT The_DT protocol_NN takes_VBZ about_RB 5_CD to_TO 6_CD h_NN to_TO complete_VB ._SENT The_DT cost_NN of_IN the_DT GenoType_NP test_NN (_( $13/test_NNS )_) was_VBD slightly_RB lower_JJR than_IN that_DT of_IN LiPA_NP (_( $20/test_NN )_) ._SENT In_IN our_PP$ laboratory_NN ,_, an_DT additional_JJ limitation_NN of_IN the_DT LiPA_NP assay_NN was_VBD the_DT requirement_NN for_IN highly_RB stringent_JJ reaction_NN conditions_NNS ,_, also_RB pointed_VBD out_RP by_IN Tortoli_NP et_FW al._FW ._SENT When_WRB processing_VBG a_DT large_JJ number_NN of_IN samples_NNS (_( >20_NN )_) ,_, temperature_NN does_VBZ not_RB remain_VB optimal_JJ during_IN the_DT manual_JJ pipetting_VBG steps_NNS despite_IN prewarming_VBG of_IN reagents_NNS ._SENT This_DT results_NNS in_IN faint_JJ bands_NNS in_IN hybridization_NN temperature_NN controls_NNS ,_, indicating_VBG that_IN the_DT test_NN is_VBZ not_RB carried_VBN out_RP properly_RB ._SENT The_DT GenoType_NP test_NN has_VBZ no_DT temperature_NN control_NN ,_, but_CC if_IN the_DT hybridization_NN temperature_NN was_VBD too_RB low_JJ ,_, several_JJ bands_NNS would_MD be_VB seen_VBN on_IN the_DT strips_NNS ._SENT Since_IN GenoType_NP results_NNS were_VBD always_RB easy_JJ to_TO interpret_VB ,_, even_RB with_IN large_JJ numbers_NNS of_IN samples_NNS ,_, we_PP believe_VBP that_IN it_PP is_VBZ not_RB as_RB sensitive_JJ to_TO temperature_NN changes_NNS as_IN the_DT LiPA_NP assay_NN ._SENT In_IN 2000_CD ,_, a_DT total_NN of_IN 775_CD mycobacterial_JJ isolates_NNS were_VBD obtained_VBN from_IN clinical_JJ specimens_NNS in_IN Finland_NP ;_: 51.5_CD %_NN of_IN them_PP belonged_VBD to_TO the_DT M._NP tuberculosis_NN complex_NN ,_, while_IN 48.5_CD %_NN were_VBD MOTT_NP ._SENT The_DT LiPA_NP test_NN would_MD have_VB covered_VBN 89.3_CD %_NN (_( 692_CD of_IN 775_CD )_) and_CC the_DT GenoType_NP test_NN 90.7_CD %_NN (_( 703_CD of_IN 775_CD )_) of_IN the_DT isolates_NNS ._SENT If_IN the_DT current_JJ identification_NN methods_NNS were_VBD replaced_VBN with_IN a_DT strip-based_JJ method_NN ,_, only_RB 10_CD %_NN of_IN the_DT isolates_NNS would_MD need_VB to_TO be_VB identified_VBN by_IN sequencing_NP ._SENT Even_RB though_IN the_DT overall_JJ difference_NN between_IN species_NN coverage_NN and_CC performance_NN of_IN the_DT two_CD strip_NN tests_NNS is_VBZ narrow_JJ ,_, two_CD clinically_RB important_JJ species_NNS ,_, M._NP fortuitum_NP and_CC M._NP malmoense_NN ,_, are_VBP identified_VBN only_RB with_IN the_DT GenoType_NP test_NN ,_, rendering_VBG this_DT assay_NN more_RBR suitable_JJ for_IN our_PP$ laboratory_NN ._SENT However_RB ,_, the_DT AccuProbe_NP test_NN is_VBZ still_RB much_RB faster_JJR and_CC easier_JJR to_TO perform_VB than_IN the_DT strip_NN assays_NNS ._SENT This_DT is_VBZ especially_RB important_JJ for_IN rapid_JJ identification_NN of_IN the_DT members_NNS of_IN the_DT M._NP tuberculosis_NN complex_NN ._SENT In_IN our_PP$ laboratory_NN ,_, the_DT strip_NN assays_NNS would_MD thus_RB be_VB best_RBS suited_VBN for_IN the_DT identification_NN of_IN MOTT_NP ._SENT We_PP conclude_VBP that_IN both_DT line_NN probe_NN assays_NNS were_VBD rapid_JJ ,_, reliable_JJ ,_, and_CC specific_JJ ,_, with_IN easy-to-understand_NN ,_, straightforward_JJ test_NN protocols_NNS ._SENT The_DT GenoType_NP test_NN was_VBD found_VBN more_RBR suitable_JJ for_IN the_DT identification_NN of_IN mycobacteria_NNS isolated_VBN from_IN Finland_NP ,_, due_JJ to_TO its_PP$ wider_JJR strain_NN selection_NN ,_, less_RBR stringent_JJ reaction_NN conditions_NNS ,_, cost-effectiveness_NN ,_, and_CC better_JJR performance_NN ._SENT Studies_NNS are_VBP under_IN way_NN to_TO evaluate_VB this_DT test_NN in_IN clinical_JJ practice_NN ._SENT 